Sonidegib tolerability across 30-months: Results from the phase 2 randomized BOLT trial

被引：0
|
作者：
Stockfleth, E. [1 ]
机构：
[1] Univ Hautklin Bochum, St Josef Hosp, Bochum, Germany
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2017年 / 137卷 / 10期
关键词：
D O I：
10.1016/j.jid.2017.07.739
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
542
引用
收藏
页码：S285 / S285
页数：1
相关论文
共 50 条
  • [1] Sonidegib duration of response across 30 months: Results from the randomized phase 2 BOLT trial
    Stockfleth, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S284 - S284
  • [2] Sonidegib safety at 30 months: Results from the phase 2 BOLT trial
    Guminski, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 68 - 68
  • [3] Long-term effects of sonidegib on tumor burden: 30-month results from the phase 2 randomized bolt trial
    Dummer, R.
    Migden, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Sonidegib's duration of response: Results from the pivotal phase 2 BOLT study over 30 months in patients with locally advanced basal cell carcinoma
    Migden, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 39 - 39
  • [5] Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months
    Dummer, Reinhard
    Lear, John T.
    Guminski, Alex
    Leow, Liang Joo
    Squittieri, Nicholas
    Migden, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (04) : 1162 - 1164
  • [6] Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months''
    Villani, Alessia
    Fabbrocini, Gabriella
    Costa, Claudia
    Scalvenzi, Massimiliano
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (06) : E299 - E300
  • [7] Sonidegib's duration of response: Pivotal phase 2 BOLT study over 30 months in patients with locally advanced basal cell carcinoma
    Guminski, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 31 - 31
  • [8] Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial
    Chen, Leon
    Aria, Alexander B.
    Silapunt, Sirunya
    Lee, Heng-Huan
    Migden, Michael R.
    FUTURE ONCOLOGY, 2018, 14 (06) : 515 - 525
  • [9] Sonidegib preplanned subgroup analyses of objective response rates: 30-month results from the BOLT study
    Lear, John T.
    Migden, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB267 - AB267
  • [10] RANDOMIZED TRIAL OF EARLY CAPPING IN NEONATAL POSTHEMORRHAGIC VENTRICULAR DILATATION - RESULTS AT 30 MONTHS
    WHITELAW, A
    MUTCH, L
    STEWART, A
    ELBOURNE, D
    FOOKS, J
    GRANT, A
    HUNT, S
    JOHNSON, A
    COOKE, R
    RENNIE, J
    WEINDLING, M
    HOPE, P
    HAMILTON, P
    WILKINSON, A
    ROCHEFORT, M
    GANDY, G
    MORLEY, C
    HEY, E
    PARKIN, J
    HARVEY, D
    MILLIGAN, D
    PEARSE, R
    SMITH, M
    BRIDSON, J
    GRIFFIN, E
    LISSAUER, T
    RIVERS, R
    DRAYTON, M
    FLEMING, P
    SPEIDEL, B
    GORMAN, W
    OBRIEN, N
    ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1994, 70 (02): : F129 - F136
12345